-
Actinium | Highlights Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Exposition
NYSE: ATNM NEW YORK, Dec. 8, 2023 /PRNewswire/ — Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that clinical data from its Iomab-B and Actimab-A programs will be featured in four presentations at the 65th Annual American Society of Hematology Annual Meeting &…
-
Incyte | Spotlighting More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting
Incyte (NASDAQ:INCY) will present more than 40 abstracts at the ASH 2023 conference, featuring data from its hematology and oncology products. The Plenary Scientific Session will showcase the results of the AGAVE-201 trial evaluating axatilimab in patients with chronic GVHD. Incyte will also host an analyst and investor event to discuss the key data presentations…
-
Aptose Biosciences | Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting
NASDAQ: APTO Aptose Biosciences Inc. announced that clinical data for tuspetinib has been selected for oral presentation at the 65th American Society of Hematology Annual Meeting. The presentation will include safety and efficacy data from Aptose’s ongoing APTIVATE trial of tuspetinib in relapsed/refractory acute myeloid leukemia patients. The presentation will take place on December 9,…